AMUNDI MSCI USA ESG LEADERS UCITS ETF Acc (ISAD) Trades

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed the company's newly-announced research license agreement with Catalent with Proactive's Stephen Gunnion. Buck shared insights into Lisata’s preclinical evaluation of certepetide using Catalent’s SMARTag antibody-drug conjugate (ADC) platform.. She explained that Catalent would assume all R&D costs, while Lisata provides consulting and stands to receive both upfront and potential milestone payments. Certepetide is described as a unique cyclic non-amino acid peptide, designed to bind to receptors commonly found on solid tumors. Upon binding, it transforms to activate a transport mechanism that boosts therapeutic penetration. "It can work with current therapies and emerging therapies," Buck said, emphasizing its compatibility and favorable safety profile. Buck further discussed the growing relevance of ADCs in oncology. She described ADCs as “biological missiles,” targeting tumors while minimizing harm to healthy tissues. When combined with certepetide, ADCs benefit from deeper tumor penetration and potential immunomodulation, making treatment more effective. The company expects initial data from this collaboration before the end of Q2 2025. Positive results could lead to a deeper relationship with Catalent. Visit Proactive's YouTube channel for more company interviews and updates. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future content. #LisataTherapeutics #KristenBuck #Certepetide #AntibodyDrugConjugates #ADC #OncologyInnovation #CancerResearch #Catalent #BiotechNews #TumorTargeting #ImmunoOncology #SMARTagPlatform

Ananda Pharma CEO Melissa Sturgess joined Steve Darling from Proactive to announce the company’s shares have begun trading on the OTCQB market in the United States, a strategic move that expands Ananda’s visibility and access to U.S. investors. The UK-based biopharmaceutical company is focused on developing regulatory-approved cannabinoid medicines for complex and chronic medical conditions. Sturgess emphasized the significance of entering the U.S. market, not only from a capital markets perspective but also as a key future territory for Ananda’s clinical and commercial ambitions. She also highlighted recent progress in the company’s clinical development pipeline, particularly around its lead investigational drug candidate, MRX1. Ananda recently received approval from the Alfred Hospital Human Research Ethics Committee in Australia to initiate a Phase 1 pharmacokinetic study of MRX1. The study will evaluate the safety, tolerability, and pharmacokinetics of two dose levels of the CBD-based drug in a cohort of 20 healthy adult volunteers—10 biological males and 10 biological females—to address known sex differences in CBD metabolism. MRX1 is a high-purity, pharmaceutical-grade cannabidiol (CBD) formulation developed under rigorous quality standards to ensure consistency, safety, and clinical reliability. It is intended for the treatment of chronic inflammatory pain conditions, where current treatment options often fall short in efficacy or come with undesirable side effects. Sturgess noted that this ethics approval marks a critical milestone in the company’s journey toward regulatory approval and commercial readiness. The trial is expected to generate key safety and dosing data to support future Phase 2 studies targeting patients with unmet needs in chronic pain management. #proactiveinvestors #aqse #ana #cbd #otcqb #MRX1 #CBDDrugDevelopment #CannabinoidTherapy #ClinicalTrials #FDAApproval #PharmaNews #BiotechStocks #OTCQB #GWPharma #CBDMedicine #ChronicPainTreat

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company’s new strategic partnership with US-based Heureka Labs, a spinoff of Duke University, to enhance its gene therapy research using AI technology. Leire said: “Every biotech in gene therapy should have an AI component. If you don't have that, you miss a critical tool to unlock value for your shareholders.” He stressed the need for a multi-omics approach—genomic, transcriptomic, and proteomic—to better understand gene expression and drug response, which traditional analysis methods struggle to fully capture. The partnership with Heureka Labs, which integrates deep AI and biological expertise, will initially support Genflow’s lead candidate, GF-1002, a SIRT-6 gene therapy targeting MASH (metabolic dysfunction-associated steatohepatitis). AI will help the company analyse complex preclinical data, including insights from nearly 700 mice tested, to understand mechanisms of action and identify likely responders—crucial in discussions with regulators such as the FDA and EMA. Leire also emphasised that the collaboration is scalable across Genflow’s pipeline, helping unlock synergies between programmes in liver, muscle, and eye diseases. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future content. #GenflowBiosciences #GeneTherapy #AIinBiotech #BiotechNews #MASH #SIRT6 #HeurekaLabs #DrugDevelopment #MultiOmics #BiotechPartnership #FDA #EMA #PreclinicalResearch

IXICO plc CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s strategy for innovation, leadership, and growth in the neurodegenerative disease space. Goorden outlined how IXICO’s precision medicine platform, TTNx, uses AI to analyse imaging data for pharmaceutical and biotech companies developing new drugs, particularly in Alzheimer’s, Parkinson’s, and Huntington’s diseases. The CEO emphasised that the company's focus remains on expanding its portfolio, enhancing analytics within existing programs, and tapping into emerging opportunities like blood-based biomarkers. “You may know that IXICO is an absolute leader in especially rare diseases, Huntington's disease and so on, but we've really seen that expansion of portfolio,” Goorden said. He also discussed the company’s strategic pillars: Innovate, Lead, and Scale. This includes integrating new algorithms, raising the company’s voice in the global precision medicine market, and strengthening its US operations to support further growth. Goorden noted that IXICO is seeing increased engagement from partners seeking FDA approvals who rely on gold-standard imaging for validation. He also mentioned the company’s recent hires and commitment to driving more partnerships throughout 2025. Visit Proactive’s YouTube channel for more exclusive interviews and insights. Don’t forget to like this video, subscribe to our channel, and turn on notifications for future updates. #IXICO #BramGoorden #PrecisionMedicine #NeurodegenerativeDiseases #AlzheimersResearch #ParkinsonsDisease #DrugDevelopment #AIinHealthcare #Biomarkers #ClinicalTrials #HealthcareInnovation #FDAapproval